Press Releases

 Filter by Provider

Custom Commercial Canopies, Custom Commercial Awnings, and Custom Canopies. Custom Metal Canopy, Commercial Building Canopies, Commercial Canopy Manufacturer, and Custom Built Canopies.

NEW YORK, NY - January 9, 2026 - Wavytalk, a brand synonymous with innovation and trust in the hair styling industry, today announced a landmark expansion with the launch of its official Wavytalk hair removal device, the Wavytalk Bare It . This move marks Wavytalk's strategic entry into the advanced personal care market, bringing its legacy of user-centric design and engineering excellence to solve one of the most universal beauty challenges: unwanted hair. The device is set to launch on Amazon on January 5, 2026.

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.“Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress,” said Dr. Musunuri. “This premier conference is the optimal way to kick off Ocugen’s catalyst-rich 2026 and engage in critical conversations with potential strategic partners and the investment community.”In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will be on site in San Franciso all week to conduct one-on-one meetings highlighting the Company’s business strategy on the path toward filing three BLAs in the next two years including the rolling BLA of OCU400 for retinitis pigmentosa this year.Details regarding the presentation are as follows:Date: Thursday, January 15, 2026Time: 9:45 - 10:25 a.m. PST Location: Colonial Room, MezzanineA live video webcast of the presentation will be available on the events page of the Ocugen investor site. The webcast replay will be available for a limited time following the event.About Ocugen, Inc.Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.Contact:Tiffany HamiltonAVP, Head of CommunicationsTiffany.Hamilton@ocugen.com

Kitchen Redesign in Pinecrest, Palmetto Bay, Coral Gables, Ocean Reef, Miami Lakes, and Miami Beach, FL. Kitchen Design, Kitchen Remodeling, and Custom Kitchen Cabinets.

The crypto market has a way of revealing its most interesting stories when momentum starts to shift. On one side, established networks like Litecoin and Bitcoin continue to move with the confidence of assets that have survived multiple cycles. On the other hand, a new narrative is forming quietly, but quickly, inside a fast-moving crypto […]

FinFusion Exchange has entered the SEC disclosure framework, aligning its corporate governance with U.S. regulatory transparency standards while establishing a more comprehensive compliance structure for its U.S. operations.

McGraw Hill, Inc. (NYSE: MH), a leading global provider for education solutions from preK-12 through higher education and professional learning, will report fiscal third quarter financial results for the period ended December 31, 2025, on Wednesday, February 11, 2026.

Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors.

Celebration, FL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech enterprise, today announced an initial closing of an $11,000,000 note under its previously announced $250 million private placement convertible note facility (the “Note Facility”). The Company’s total available financing capacity, including the initial closing, is $1.25 billion when combined with its existing $1 billion equity purchase facility. La Rosa will deploy this capital to establish a strategic reserve, providing the liquidity and financial agility to scale its AI infrastructure strategy and develop a premium real estate portfolio of advanced data center facilities optimized for AI workloads. 

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease.

The "Aircraft Avionics MRO Market Size, Share, Trends, Dynamics, Forecast, & Growth Analysis: 2025-2035" report has been added to ResearchAndMarkets.com's offering.

Polestar (Nasdaq: PSNY) retail sales amounted to an estimated 15,608 cars in Q4 2025, up 27% versus Q4 2024. For the full year, retail sales totalled approximately 60,119 cars, a growth of 34% compared to 2024.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026.

Molson Coors Beverage Company (NYSE: TAP, TAP.A; TSX: TPX.B, TPX.A) will release its 2025 Fourth Quarter and Full Year earnings results on Wednesday, February 18, 2026 at approximately 4 p.m. Eastern Time.

Upbound Group, Inc. (“Upbound” or the “Company”) (NASDAQ: UPBD), a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of underserved consumers, today announced that Fahmi Karam, CEO, and Hal Khouri, CFO, will participate in a Fireside Chat presentation at the 2026 ICR Conference in Orlando, Florida, on Tuesday, January 13, at 3:30 PM ET. A live webcast of the presentation will be available at https://investor.upbound.com.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).

The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets.

Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, today announced positive topline data from a Phase 1b/2a clinical trial evaluating its novel immune-enabling antibody therapy, CMTX-101, in the treatment of people with cystic fibrosis (pwCF). These findings support further development of CMTX-101 in a Phase 2 bronchiectasis trial.

Nu Skin Enterprises Inc. (NYSE: NUS) today announced president and CEO Ryan Napierski will participate in a moderated fireside chat to discuss company strategy and the state of the business on Monday, Jan. 12. The discussion will include the company’s plans in 2026 for launching its Prysm iO intelligent wellness device and future opportunities in emerging markets, including India.

Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference

New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation

GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates.

SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI), taking place January 8-10 in San Francisco, CA.

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin’s VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.

Strategic Transaction Accelerates iHerb’s U.S. Business and Solidifies Commitment to the Vitamins, Minerals and Supplements Category

WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today provided an update on the regulatory approval of Anaphylm™ and its business.

SHENZHEN, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it has entered into a strategic partnership with Xiaoe Inc. (“Xiaoe”) to integrate its intelligent push notification solution, JPush, into Xiaoe’s flagship private domain SaaS platform.

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule.

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week.

ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that its executive team will attend Biotech Showcase 2026 in San Francisco, January 12-14, to meet with innovative biotech sponsors and highlight the company’s newly launched Early Phase Center of Excellence for Biotechs.

Selling products across borders is exciting, but the reality often feels messier than expected. Many online retailers only discover the hidden challenges once something goes wrong. One issue that quietly causes the most damage is language and how small wording choices affect financial accuracy. It’s not just about translating product descriptions or checkout instructions. E-commerce translation services influence far more than product pages; they reach pricing logic, tax explanations, and even internal reporting. A small misinterpretation can snowball into refunds, complaints, and even legal issues.

Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for December 2025 on Friday, January 9, 2026.

Lindsay Corporation (NYSE: LNN), a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology, announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.37 per share, payable February 27, 2026, to shareholders of record at the close of business on February 13, 2026.

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) (“Brookfield Asset Management”) today announced it has received the requisite approval for the renewal of its normal course issuer bid providing the option to purchase up to 36,946,177 Class A Limited Voting Shares (“Class A Shares”), representing approximately 10% of the public float of Brookfield Asset Management’s outstanding Class A Shares. Purchases under the bid will be made on the open market through the facilities of the New York Stock Exchange (“NYSE”), Toronto Stock Exchange (“TSX”), and/or alternative trading systems. The period of the normal course issuer bid will extend from January 13, 2026 to January 12, 2027, or an earlier date should Brookfield Asset Management complete its purchases. Brookfield Asset Management will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted.

Singapore, 9th Jan 2026 – As global digital asset markets continue to mature, KBY Exchange is emerging as a trading platform focused on long-term stability, risk discipline, and sustainable growth rather than short-term speculation.

Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2025 (4Q25), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on February 11, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Tamarac, located at 6001 N University Drive in Tamarac, Fla. It is the Company’s 31st dispensary in Florida and 72nd nationwide.

Carter’s, Inc. (NYSE:CRI), North America’s largest and most-enduring apparel company exclusively for babies and young children, today announced preliminary net sales results for the fourth quarter and fiscal year 2025, participation at an upcoming investor conference, and an addition to the Company’s management team.

MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and the clinical pipeline. These updates will be discussed during Liquidia’s participation in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–14, 2026, in San Francisco. The Company plans to report fully audited financial results for the year ended December 31, 2025, in February 2026.

The new portable AI companion charm combines emotional interaction, personalized growth, and trend-forward design.

Las Vegas, Nevada--(Newsfile Corp. - January 9, 2026) - At CES 2026, Lgenie officially launched its innovative industrial-grade intelligent agent...

Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH).

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2026) - International Lithium Corp. (TSXV: ILC) (OTCQB: ILHMF) (FSE: IAH) ("ILC" or...

Linde (Nasdaq: LIN) will release its fourth quarter 2025 financial results by 06:00 EST/midday CET on Thursday, February 5, 2026. The Company will host and webcast its conference call at 09:00 EST/15:00 CET, which will be available to the public and the media in listen-only mode.

Oklo Inc. (NYSE: OKLO) (Oklo), an advanced nuclear technology company, announced an agreement with Meta Platforms, Inc. (Nasdaq: META) that advances Oklo’s plans to develop a 1.2 GW power campus in Pike County, Ohio, to support Meta’s data centers in the region. The agreement provides a mechanism for Meta to prepay for power and provide funding to advance project certainty for Oklo’s Aurora powerhouse deployment.

Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale.

Pacifico Energy Vietnam (“PEV”), the Vietnam-based development platform of Pacifico Energy Group (“PEG”), a leading global energy infrastructure developer, today announced the commencement of commercial operations at its 30 MW Sunpro Wind Farm (“Sunpro”), adding new power capacity to Vietnam’s national grid, supporting the country’s transition to clean energy. Located in Thới Thuận Commune, Vĩnh Long Province in the Mekong Delta, Sunpro achieved commercial operations on December 19, 2025. PEG owns 100% of Sunpro, which is backed by a 20-year feed-in tariff with Vietnam Electricity Group (“EVN”), providing stable, long-term revenue.

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”), have until March 9, 2026 to seek appointment as lead plaintiff of the Ardent Health class action lawsuit. Captioned Postiwala v. Ardent Health, Inc., No. 26-cv-00022 (M.D. Tenn.), the Ardent Health class action lawsuit charges Ardent Health and certain of Ardent Health’s top executives with violations of the Securities Exchange Act of 1934.